Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2021 Earnings Results

Rhythm Pharmaceuticals Misses on EPS, Stock Down 4.54%

Rhythm Pharmaceuticals reported a wider-than-expected loss per share, leading to a 4.54% decline in stock price. Investors may be concerned about the lack of revenue details and forward guidance. The management's cautious tone suggests they are navigating challenges while aiming for future growth.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.70	N/A	+6.04%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management conveyed a cautious optimism about future developments. They emphasized their focus on product advancement despite current challenges.

Management highlighted ongoing efforts to enhance product development.

They acknowledged challenges but expressed commitment to long-term goals.

Rhythm Pharmaceuticals Misses on EPS, Stock Down 4.54%

Key numbers

Management commentary

Rhythm Pharmaceuticals, Inc.

More earnings this week

Rhythm Pharmaceuticals Misses on EPS, Stock Down 4.54%

Key numbers

Management commentary